Factors associated with typical enteropathogenic


Journal

Epidemiology and infection
ISSN: 1469-4409
Titre abrégé: Epidemiol Infect
Pays: England
ID NLM: 8703737

Informations de publication

Date de publication:
16 11 2020
Historique:
pubmed: 17 11 2020
medline: 26 1 2021
entrez: 16 11 2020
Statut: epublish

Résumé

Typical enteropathogenic Escherichia coli (tEPEC) infection is a major cause of diarrhoea and contributor to mortality in children <5 years old in developing countries. Data were analysed from the Global Enteric Multicenter Study examining children <5 years old seeking care for moderate-to-severe diarrhoea (MSD) in Kenya. Stool specimens were tested for enteric pathogens, including by multiplex polymerase chain reaction for gene targets of tEPEC. Demographic, clinical and anthropometric data were collected at enrolment and ~60-days later; multivariable logistic regressions were constructed. Of 1778 MSD cases enrolled from 2008 to 2012, 135 (7.6%) children tested positive for tEPEC. In a case-to-case comparison among MSD cases, tEPEC was independently associated with presentation at enrolment with a loss of skin turgor (adjusted odds ratio (aOR) 2.08, 95% confidence interval (CI) 1.37-3.17), and convulsions (aOR 2.83, 95% CI 1.12-7.14). At follow-up, infants with tEPEC compared to those without were associated with being underweight (OR 2.2, 95% CI 1.3-3.6) and wasted (OR 2.5, 95% CI 1.3-4.6). Among MSD cases, tEPEC was associated with mortality (aOR 2.85, 95% CI 1.47-5.55). This study suggests that tEPEC contributes to morbidity and mortality in children. Interventions aimed at defining and reducing the burden of tEPEC and its sequelae should be urgently investigated, prioritised and implemented.

Identifiants

pubmed: 33190663
doi: 10.1017/S0950268820002794
pii: S0950268820002794
pmc: PMC7770376
doi:

Types de publication

Journal Article Research Support, Non-U.S. Gov't Research Support, U.S. Gov't, P.H.S.

Langues

eng

Sous-ensembles de citation

IM

Pagination

e281

Références

BMC Pediatr. 2004 Feb 05;4:2
pubmed: 15005806
BMC Infect Dis. 2007 Aug 09;7:92
pubmed: 17688682
Clin Infect Dis. 2012 Dec;55 Suppl 4:S232-45
pubmed: 23169936
J Infect Dis. 1989 Jul;160(1):131-5
pubmed: 2567320
Clin Microbiol Rev. 1998 Jan;11(1):142-201
pubmed: 9457432
Am J Trop Med Hyg. 2005 Dec;73(6):1151-8
pubmed: 16354829
Epilepsia. 1998 Sep;39(9):960-4
pubmed: 9738675
Int J Epidemiol. 1997 Oct;26(5):1090-6
pubmed: 9363532
BMC Public Health. 2015 Oct 03;15:1008
pubmed: 26433396
BMJ. 2007 Apr 14;334(7597):782
pubmed: 17353208
Emerg Infect Dis. 2002 May;8(5):508-13
pubmed: 11996687
Int J Epidemiol. 2012 Aug;41(4):977-87
pubmed: 22933646
Cell Microbiol. 2008 Aug;10(8):1735-45
pubmed: 18433466
PLoS Negl Trop Dis. 2015 May 15;9(5):e0003791
pubmed: 25978422
Clin Infect Dis. 2012 Dec;55 Suppl 4:S225-31
pubmed: 23169935
Trans R Soc Trop Med Hyg. 2008 Sep;102(9):852-6
pubmed: 18455741
AIDS. 2014 Sep 24;28(15):2287-96
pubmed: 25028987
Lancet Infect Dis. 2017 Sep;17(9):909-948
pubmed: 28579426
Lancet. 2013 Jul 20;382(9888):209-22
pubmed: 23680352
Lancet. 2016 Sep 24;388(10051):1291-301
pubmed: 27673470
Clin Infect Dis. 2012 Dec;55 Suppl 4:S294-302
pubmed: 23169941
J Am Coll Nutr. 1999 Aug;18(4):303-8
pubmed: 12038472
Clin Infect Dis. 2012 Dec;55 Suppl 4:S215-24
pubmed: 23169934
Am J Trop Med Hyg. 2017 Jul;97(1):248-258
pubmed: 28719331
Am J Trop Med Hyg. 2013 Jul;89(1 Suppl):29-40
pubmed: 23629929
Clin Infect Dis. 2012 Dec;55 Suppl 4:S303-11
pubmed: 23169942
J Infect Dis. 1991 Jun;163(6):1247-55
pubmed: 1903799
Curr Opin Infect Dis. 2011 Oct;24(5):478-83
pubmed: 21857511
J Med Microbiol. 2006 Sep;55(Pt 9):1165-1174
pubmed: 16914645
Epidemiol Rev. 1984;6:31-51
pubmed: 6386503
Lancet Glob Health. 2020 Feb;8(2):e204-e214
pubmed: 31864916
BMC Med. 2014 Jan 09;12:5
pubmed: 24405531
J Acquir Immune Defic Syndr. 2010 Jan;53(1):14-9
pubmed: 19801943
Rev Infect Dis. 1987 Jan-Feb;9(1):28-53
pubmed: 3547577
Bull World Health Organ. 1991;69(5):609-21
pubmed: 1835675

Auteurs

K Fagerli (K)

National Center for Emerging and Zoonotic Infectious Diseases, Centers for Disease Control and Prevention, Atlanta, GA, USA.

R Omore (R)

Kenya Medical Research Institute, Kisumu, Kenya.

S Kim (S)

National Center for Emerging and Zoonotic Infectious Diseases, Centers for Disease Control and Prevention, Atlanta, GA, USA.

J B Ochieng (JB)

Kenya Medical Research Institute, Kisumu, Kenya.

T L Ayers (TL)

National Center for Emerging and Zoonotic Infectious Diseases, Centers for Disease Control and Prevention, Atlanta, GA, USA.

J Juma (J)

Kenya Medical Research Institute, Kisumu, Kenya.

T H Farag (TH)

Center for Vaccine Development and Global Health, University of Maryland School of Medicine, Baltimore, MD, USA.

D Nasrin (D)

Center for Vaccine Development and Global Health, University of Maryland School of Medicine, Baltimore, MD, USA.

S Panchalingam (S)

Center for Vaccine Development and Global Health, University of Maryland School of Medicine, Baltimore, MD, USA.

R M Robins-Browne (RM)

Peter Doherty Institute for Infection and Immunity, The University of Melbourne, Melbourne, Australia.

J P Nataro (JP)

Center for Vaccine Development and Global Health, University of Maryland School of Medicine, Baltimore, MD, USA.

K L Kotloff (KL)

Center for Vaccine Development and Global Health, University of Maryland School of Medicine, Baltimore, MD, USA.

M M Levine (MM)

Center for Vaccine Development and Global Health, University of Maryland School of Medicine, Baltimore, MD, USA.

J Oundo (J)

Kenya Medical Research Institute, Kisumu, Kenya.

M B Parsons (MB)

National Center for Emerging and Zoonotic Infectious Diseases, Centers for Disease Control and Prevention, Atlanta, GA, USA.

K F Laserson (KF)

Center for Global Health, Centers for Disease Control and Prevention, Nairobi, Kenya.

E D Mintz (ED)

National Center for Emerging and Zoonotic Infectious Diseases, Centers for Disease Control and Prevention, Atlanta, GA, USA.

R F Breiman (RF)

Emory Global Health Institute, Emory University, Atlanta, GA, USA.

C E O'Reilly (CE)

National Center for Emerging and Zoonotic Infectious Diseases, Centers for Disease Control and Prevention, Atlanta, GA, USA.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH